{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:40:49Z","timestamp":1773283249502,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/maj.0b013e3181e99aa4","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T11:18:00Z","timestamp":1283944680000},"page":"209-217","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria"],"prefix":"10.1016","volume":"340","author":[{"given":"Karen K.","family":"Kinney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0010","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.diagmicrobio.2008.10.010","article-title":"United States resistance surveillance results for linezolid (LEADER Program for 2007)","volume":"62","author":"Jones","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/499367","article-title":"Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003","volume":"42","author":"Klevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0195-6701(93)90100-E","article-title":"Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia","volume":"25","author":"Udo","year":"1993","journal-title":"J Hosp Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0035","first-page":"707","article-title":"Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus\u2014Minnesota and North Dakota, 1997-1999","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0040","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/JCM.41.11.5113-5120.2003","article-title":"Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database","volume":"41","author":"McDougal","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1473-3099(06)70491-1","article-title":"Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies","volume":"6","author":"Aiello","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa042859","article-title":"A clone of methicillin-resistant Staphylococcus aureus among professional football players","volume":"352","author":"Kazakova","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000151107.29132.70","article-title":"Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas","volume":"24","author":"Mishaan","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.coph.2009.07.009","article-title":"An update on community-associated MRSA virulence","volume":"9","author":"Kobayashi","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1128\/JCM.44.1.108-118.2006","article-title":"Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States","volume":"44","author":"Tenover","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0070","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1073\/pnas.0710217105","article-title":"Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification","volume":"105","author":"Kennedy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0075","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/499815","article-title":"Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections","volume":"42","author":"Seybold","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0085","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/491711","article-title":"Vancomycin resistance in gram-positive cocci","volume":"42","author":"Courvalin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0090","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1086\/533592","article-title":"Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains","volume":"46","author":"Sakoulas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2004.09.005","article-title":"Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin","volume":"51","author":"Rybak","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0100","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0105","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0110","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0115","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0120","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0125","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0140","series-title":"Performance standards for antimicrobial disc susceptibility tests: 15th information supplement. Report no. M100-S15","author":"Clinical Laboratory Standards Institute","year":"2005"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0150","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1086\/368128","article-title":"Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?","volume":"187","author":"Sakoulas","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0155","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1128\/AAC.48.3.1024-1027.2004","article-title":"Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II","volume":"48","author":"Verdier","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0165","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0170","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0175","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.02135-08","article-title":"Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years","volume":"47","author":"Musta","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0180","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0190","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/422458","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"39","author":"Cosgrove","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0200","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkn329","article-title":"Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"62","author":"Lodise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/dkm445","article-title":"Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"61","author":"Moise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0210","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/JB.185.24.7103-7110.2003","article-title":"Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus","volume":"185","author":"Sieradzki","year":"2003","journal-title":"J Bacteriol"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0215","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0163-4453(09)60003-7","article-title":"Infections caused by Gram-positive bacteria: a review of the global challenge","volume":"59","author":"Woodford","year":"2009","journal-title":"J Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2180-8-39","article-title":"Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"8","author":"Howden","year":"2008","journal-title":"BMC Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1086\/596511","article-title":"Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection","volume":"199","author":"Peleg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0235","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard,","author":"Clinical Laboratory Standards Institute","year":"2009"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0240","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0245","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0250","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0265","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1128\/JCM.01262-06","article-title":"Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center","volume":"45","author":"Maor","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0270","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/596629","article-title":"Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia","volume":"199","author":"Maor","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0275","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","article-title":"Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore","volume":"28","author":"Fong","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0280","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1345\/aph.1M526","article-title":"Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance","volume":"44","author":"Rong","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0285","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1086\/533594","article-title":"Pneumonia caused by methicillin-resistant Staphylococcus aureus","volume":"46","author":"Rubinstein","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0290","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1086\/432475","article-title":"Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection","volume":"41","author":"Gonzalez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0295","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","article-title":"Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients","volume":"359","author":"Gillet","year":"2002","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0300","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0305","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1378\/chest.113.2.412","article-title":"The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia","volume":"113","author":"Kollef","year":"1998","journal-title":"Chest"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0310","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/377540","article-title":"Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci","volume":"37","author":"Kim","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0315","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0163-4453(09)60005-0","article-title":"Treatment options for nosocomial pneumonia due to MRSA","volume":"59","author":"Niederman","year":"2009","journal-title":"J Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0320","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0325","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0330","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2009.09.013","article-title":"Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"35","author":"Beibei","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0340","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0345","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0350","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections","volume":"144","author":"King","year":"2006","journal-title":"Ann Intern Med"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0355","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1086\/533593","article-title":"Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0360","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/525536","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0365","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0370","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/14656560902811811","article-title":"Therapeutic options for infections due to vancomycin-resistant enterococci","volume":"10","author":"Wang","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0375","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jinf.2005.07.011","article-title":"Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital","volume":"52","author":"Poh","year":"2006","journal-title":"J Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0380","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ajic.2006.05.220","article-title":"Antimicrobial resistance in gram-positive bacteria","volume":"34","author":"Rice","year":"2006","journal-title":"Am J Infect Control"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0385","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/mic.0.026385-0","article-title":"The ecology, epidemiology and virulence of Enterococcus","volume":"155","author":"Fisher","year":"2009","journal-title":"Microbiology"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0390","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1469-0691.2010.03214.x","article-title":"Management of multi-drug resistant enterococcal infections","volume":"6","author":"Arias","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0395","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin-resistant enterococcal infections","volume":"342","author":"Murray","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0400","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.47.19046-en","article-title":"Emergence and spread of vancomycin resistance among enterococci in Europe","volume":"13","author":"Werner","year":"2008","journal-title":"Euro Surveill"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0405","first-page":"iii41","article-title":"Future directions with daptomycin","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0410","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0415","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0149-2918(01)80028-X","article-title":"Quinupristin\/dalfopristin: a therapeutic review","volume":"23","author":"Allington","year":"2001","journal-title":"Clin Ther"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10096-007-0389-y","article-title":"New antimicrobial agents as therapy for resistant gram-positive cocci","volume":"27","author":"Lentino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0425","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1086\/323899","article-title":"Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin\/dalfopristin","volume":"33","author":"Linden","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0430","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0435","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/421471","article-title":"Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA","volume":"190","author":"Meka","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0440","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00231-08","article-title":"First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States","volume":"52","author":"Mendes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0445","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/650574","article-title":"Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus","volume":"50","author":"Morales","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0450","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/joc.2009.21.2.165","article-title":"Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study","volume":"21","author":"Papadopoulos","year":"2009","journal-title":"J Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0455","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0460","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1473-3099(09)70200-2","article-title":"Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions","volume":"9","author":"Moise","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0465","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1345\/aph.1M264","article-title":"Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis","volume":"44","author":"Bliziotis","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0470","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0475","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00402-008-0772-x","article-title":"Daptomycin in bone and joint infections: a review of the literature","volume":"129","author":"Rice","year":"2009","journal-title":"Arch Orthop Trauma Surg"},{"issue":"suppl 4","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0480","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/S0924-8579(09)70005-6","article-title":"A review of tigecycline-the first glycylcycline","volume":"32","author":"Peterson","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0485","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e99aa4_bb0490","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0495","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2008.09.001","article-title":"Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin","volume":"63","author":"Bergallo","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0500","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0505","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","article-title":"Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)","volume":"34","author":"Barbour","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0520","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0525","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/MCC.0b013e32832f0a74","article-title":"New treatments for methicillin-resistant Staphylococcus aureus","volume":"15","author":"Stryjewski","year":"2009","journal-title":"Curr Opin Crit Care"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0530","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/AAC.00084-09","article-title":"Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge","volume":"53","author":"Llarrull","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0535","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0540","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1345\/aph.1L167","article-title":"Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections","volume":"43","author":"Sincak","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0545","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.00413-08","article-title":"Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa","volume":"52","author":"Koga","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99aa4_bb0550","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T02:57:31Z","timestamp":1636426651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915315007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0002962915315007"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181e99aa4","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}